Exciting news for parents! On March 5th, 2025, the U.S. Food and Drug Administration (FDA) approved the first-ever nasal epinephrine spray, aptly named Neffy, designed for children as young as 4 years old. This groundbreaking product, created by ARS Pharmaceuticals, is intended for kids weighing between 33 to 66 lbs who are at risk of anaphylactic reactions.

Imagine a world where children experiencing severe allergic reactions can skip the fear of injections and opt for a quick, easy-to-use nasal spray instead. With Neffy, relief is just a spray away, and kids can feel more secure knowing there's a simpler solution to their health crisis.

Empowering Parents and Providers

To ensure effective usage, pediatric nurse practitioners (PNPs) need to stay equipped with the latest information regarding Neffy. ARS Pharma has launched a comprehensive website tailored for both healthcare providers and parents, featuring detailed instructions for administering the nasal spray. It’s vital that parents familiarize themselves with the technique — proper positioning of the device in the nostril is crucial for maximum effectiveness.

Each Neffy device contains a single dose of nasal epinephrine, so parents are advised to always carry two spray devices. As with injectable epinephrine, multiple doses may be necessary to combat an anaphylactic reaction.

Safety First: Neffy in Schools and Daycares

With Neffy now available for young children, it's essential that daycare centers and preschools have two nasal spray devices on hand. ARS Pharma has introduced the neffyinSchools Program, offering U.S. K-12 schools free cartons containing multiple Neffy doses for emergency situations. It’s critical for PNPs and school health professionals to understand this program and familiarize themselves with their state's laws regarding stocking epinephrine.

Best Practices in Pediatric Offices

Pediatric offices should incorporate Neffy into routine emergency training sessions. During these practice drills, staff can learn the location and usage protocols, ensuring they're ready for any situation that arises. Parents should also be educated on the urgency of administering Neffy at the first signs of an allergic reaction. If symptoms persist, a second dose can be given after five minutes, using a new device.

Neffy 1 mg is set to hit the market by the end of May 2025, marking a significant step forward in managing allergic reactions effectively. This innovation not only equips parents with a powerful tool to protect their children but also enhances the preparedness of healthcare providers.